chills with semaglutide Naples' Top Weight Loss Program New Research Uncovers Hidden Side

According to the authors, the risk of blindness appeared to be greatest within the first year of starting semaglutide treatment, and the total risk was higher compared to other therapies

Semaglutide (GLP-1 Program) Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the action of the bodys natural GLP-1 hormone slowing gastric emptying, increasing satiety signals to the brain, reducing appetite and cravings, and improving insulin sensitivity and blood sugar regulation

mBio 12 , e0121421 (2021)

Bushnell CD, Goldstein LB

Semaglutide does not automatically address emotional eating, poor sleep, chronic stress, or unrealistic expectations

One surprising new finding